Parnassus Investments released its third-quarter 2025 investor letter, reporting a 2.57% return for the Parnassus Core Equity Fund, trailing the S&P 500 Index’s 8.12% return. Year-to-date, the fund returned 9.89% compared to 14.83% for the index. Check the fund’s top five holdings for its best picks in 2025.

Boston Scientific Corporation (NYSE: BSX) was highlighted in the Parnassus Core Equity Fund’s third-quarter 2025 investor letter. The company manufactures medical devices in the MedSurg and Cardiovascular segments. Its stock had a one-month return of -4.86% and closed at $96.43 per share on December 22, 2025, with a market cap of $142.952 billion.

Parnassus Core Equity Fund praised Boston Scientific Corporation (NYSE: BSX) in its third-quarter 2025 investor letter, citing the company’s innovative products, market share, growth drivers, and strong leadership under CEO Mike Mahoney. The company’s strategic initiatives, R&D efforts, and global demand position it for durable growth.

Boston Scientific Corporation (NYSE: BSX) is not among the 30 most popular stocks among hedge funds, with 102 hedge fund portfolios holding its stock at the end of the third quarter. The company reported consolidated revenue of $5.065 billion in Q3 2025, representing a 20.3% growth from the same period in 2024. Consider exploring AI stocks for potential upside and lower downside risk.

Read more at Yahoo Finance: Is Boston Scientific Corp. (BSX) Positioned for Solid, Durable Growth?